Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses how the recent guideline update by the American Academy of Dermatology (AAD) affects dermatologists' atopic dermatitis (AD) treatment decisions.
In this interview, Elaine Siegfried, MD, of Saint Louis University School of Medicine, discusses the recent guideline update by the American Academy of Dermatology (AAD) on using phototherapy and systemic therapies to treat patients with atopic dermatitis (AD); she touches on how this update affects dermatologists' treatment decisions.
Siegfried diagnoses and treats skin-related disorders in infants and children; her specialties include AD, psoriasis, vascular birthmarks, and other eczemas. She is interested in research that investigates AD and pediatric drug development, as she participates in clinical trials for new eczema and psoriasis treatments. Siegfried is also a professor of pediatrics and dermatology in the Department of Pediatrics, Division of Dermatology, Saint Louis University School of Medicine.
Transcript
What impact does the AAD guideline update have on the decision-making process for dermatologists when considering different AD treatments?
I, personally, in my world, first of all, I only see children. At least 50% of my patients have atopic dermatitis. I always used to say it was 50% of my population, 90% of my time, because it's such a difficult condition that really requires customized treatment.
Having guidelines like this, and these are guidelines that are strictly geared toward adults, so it doesn't impact my practice at all for, I think the general dermatology population—and it was published in Journal of the American Academy of Dermatology, so it wasn't really so much geared toward allergists, family practice, or internists who also take care of this population of patients.
I would consider it being sort of a loose overview, but, again, even though this was just published, it is now outdated because there are at least 2 other topical medications that we use, and there's going to be newer biologic agents that are currently in the pipeline, and then emerging information about the JAK [Janus kinase] inhibitors. I think it's a very dynamic field, and because there's so many new things that are under development, guidelines are outdated once they're published.
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More